Gene therapy may become an option for the treatment of malignant tumors such as hepatocellular carcinoma ( HCC ) , once safe and efficient vector systems have been established. Due to their stability in vivo, recombinant adenoviral vectors are promising vectors for gene delivery to HCC. To study the characteristics of gene delivery into HCCs by recombinant adenoviral vectors in vivo, we established an in situ HCC model in the livers of athymic nude mice by intrahepatic injection of human HCC cells. Recombinant adenovirus vectors expressing -galactosidase ( Ad2CMVgal ) were injected via the tail vein of mice bearing HCC or directly into intrahepatic tumors. Levels of -galactosidase expression in tumor tissue and surrounding normal liver were analyzed by histochemistry or for quantification by a chemiluminescence assay in tissue homogenates. Following tail vein injection, high levels of -galactosidase expression were found in the liver, but virtually no gene expression could be detected in the tumor tissue. In contrast, after direct injection of Ad2CMVgal into intrahepatic HCCs, high levels of -galactosidase expression were detected in the tumor tissue. However, single transduced hepatocytes scattered throughout the normal liver could also be identified. These results indicate that barriers such as the endothelial lining of the tumor vasculature impair the efficiency of adenoviral vectors for gene delivery into HCCs by intravenous administration, which can be overcome by direct injection into the tumor tissue. However, due to the observed transduction of disseminated hepatocytes following intratumoral administration, additional HCC -specific targeting to further enhance the safety of adenoviral vectors may be required. Cancer Gene Therapy ( 2001 ) 8, 573 -579
H epatocellular carcinoma (HCC ) is a common malignant tumor with increasing incidence worldwide. 1, 2 The major risk factors for the development of this disease include liver cirrhosis, chronic infection with hepatitis B and hepatitis C viruses, and exposure to aflatoxins. 3 -5 HCCs are generally highly resistant to chemotherapeutic agents and radiotherapy. 6 Despite a variety of treatment options including surgical resection, chemoembolization, percutaneous injection of ethanol or acetic acid, and liver transplantation, the prognosis of individuals with HCC is poor. 7 Therefore, novel therapeutic strategies such as gene therapy are being developed.
Gene therapeutic approaches may include gene replacement such as the reintroduction of tumor-suppressor genes. 8, 9 The expression of prodrug-activating enzymes, which are able to convert prodrugs with low systemic toxicity into highly toxic metabolites and which induce a strong ''bystander effect,'' is another approach to be considered for gene therapy of HCC. 10 -14 The expression of a variety of immunomodulatory genes such as cytokines is able to induce and augment antitumor immune responses, which may be effective locally and against circulating tumor cells and micrometastases. 15 -19 These different gene therapy approaches require certain levels of efficiency and specificity regarding in vivo gene transfer into tumors. For gene replacement strategies to be successful, therapeutic genes must be expressed in all tumor cells, whereas the use of prodrug -activating genes and immunomodulatory genes may allow complete eradication of tumor cell populations even if only a small fraction of cells expresses the therapeutic gene. 18 -21 However, these approaches could also cause severe side effects by expression of potent antitumor genes in normal tissues with the result of damage by toxic or immune-mediated mechanisms. Therefore, the development of efficient and safe vector systems and their preclinical evaluation is a prerequisite for clinical applications of gene therapeutic approaches in human disease.
To assess two clinically important routes of vector administration in a relevant in vivo HCC model, in the work presented here, intravenous and direct intratumor deliveries of recombinant adenovirus vectors were analyzed to determine the efficiency of gene delivery into tumor tissue and also to assess the distribution of adenoviral transduction in nontumorous liver. The latter aspect may be particularly important to future clinical applications, as most HCC patients suffer from severe liver disease, which is a condition where additional impairment of liver function due to direct toxic effects of gene delivery vectors or to inflammatory reactions might pose a serious risk.
MATERIALS AND METHODS

Recombinant adenovirus vectors
The adenoviral vectors Ad2CMVgal -2 Ad2CMVgal -4 used were derived from a human adenovirus type 2 and carry the LacZ gene including a nuclear localization signal driven by the cytomegalovirus (CMV ) immediate early promoter. The generation of these vectors has been described previously. 22 As initial experiments showed no differences with respect to the in vivo distribution and gene expression levels between both vectors, data obtained with the respective vectors were combined and both vectors used were termed Ad2CMVgal in the following text.
Human HCC cells
The human HCC cell line Huh -7 was maintained in Dulbecco's modification of Eagle's minimum essential medium (DMEM; Sigma, St. Louis, MO ) supplemented with 10% heat -inactivated fetal bovine serum (Sigma) , 10 units/mL penicillin G, 10 g /mL streptomycin (Gibco BRL, Grand Island, NY ) , and nonessential amino acids ( Gibco BRL ) at 378C in a humidified atmosphere of 7% CO 2 .
Intrahepatic tumor model
Female BALB /c nu /nu (nude) mice were obtained from Charles River Laboratories ( Wilmington, MA ). Intrahepatic HCCs in nude mice were generated by slow intrahepatic injection of 5Â10 6 HuH -7 cells suspended in 50 L of DMEM using a 30 -gauge syringe during laparotomy. The injection site was compressed until bleeding was controlled followed by closure of the laparotomy. Macroscopically detectable tumors developed within 10 -14 days with an invasive growth pattern and displacement of normal liver tissue. These protocols were approved by the subcommittee on Animal Studies at the Massachusetts General Hospital and conformed to guidelines established by the National Institutes of Health.
Histopathology and immunohistochemistry
Formalin -fixed liver specimens were embedded in paraffin and sectioned followed by staining with hematoxylin and eosin. For immunohistological staining of proliferating cell nuclear antigen ( PCNA ) , the paraffin sections were dewaxed in xylene and rehydrated through graded alcohol series. To block endogenous peroxidase activity, the sections were quenched in 3% hydrogen peroxide in methanol and then blocked with normal serum corresponding to the animal source of the secondary antibody. Before immunostaining, the sections were digested with 10 mg /mL pepsin in 0.02 N HCl, pH 2.3, for 30 minutes at room temperature prior to hydrogen peroxide oxidation. The monoclonal antibody to PCNA ( Boehringer Mannheim, Mannheim, Germany ) was applied to the sections in a 1:160 dilution. After an overnight incubation at 48C, the sections were treated with biotinylated secondary antibody and the avidin -biotin horseradish peroxidase complex and 3,3
0 -diaminobenzidine as substrate ( Vector ABC Elite Kit; Vector Laboratories, Burlingame, CA ) following manufacturer's specifications.
In vivo gene transfer
Ad2CMVgal at a dose of 1Â10 10 infectious units (IU ) was administered via injection into the tail vein or by direct injection into intrahepatic HCCs during re -laparotomy. During direct tumor injection, the tip of the needle was moved carefully within the tumor tissue to allow for even distribution of the injected solution containing the adenovirus vectors. The injection site was compressed until bleeding was controlled followed by closure of the laparotomy.
Analysis of LacZ expression
The levels of LacZ expression were evaluated 48 hours following adenovirus injection by histochemistry and by a quantitative chemiluminescence assay. For histochemistry with X -gal (5 -bromo-4 chloro -3 -indolyl --D -galactopyranoside ) staining, fresh liver specimens from different regions were immediately snap -frozen in isopentane precooled with liquid nitrogen. Fresh frozen sections of 5 m thickness were fixed in 0.5% glutaraldehyde followed by incubation in a solution containing X -gal at a concentration of 1 mg / mL in 0.1 M sodium phosphate buffer, 1 mM MgCl 2 , 5 mM K 3 Fe (CN ) 6 , and 5 mM K 4 Fe (CN ) 6 for 2 hours at 378C. Slides were counterstained with eosin and examined by light microscopy. For quantification ofgalactosidase activity in tumor and liver tissue, a chemiluminescence assay ( Galacto -star; Tropix, Bedford MA ) was used. In brief, fresh frozen tissue samples were homogenated in a lysis buffer (100 mM potassium phosphate, pH 7.8, 0.2% Triton X -100) that includes dithiothreitol ( 0.5 mM ) , phenylmethylsulfonyl fluoride ( 0.2 mM ), and leupeptin ( 5 g/ mL ) . The protein concentration of homogenates was measured by the Bio -Rad Protein assay kit ( Bio -Rad Laboratories, Hercules, CA ). The homogenates were incubated for 1 hour at 208C with substrate ( diluted 1:50 ) in a 96 -well microtiter plate and chemiluminescence was measured using a luminometer (Microlumat LB 96 P; Wallac, Gaithersburg, MD ). The -galactosidase activity was expressed as relative light units (RLU ) per microgram of protein.
RESULTS
Intrahepatic HCC model in nude mice
Localized intrahepatic tumors were detected macroscopically in 80 -90% of the mice 10 -14 days following tumor cell injection (Fig 1, A and B ) . Finally, mice developed large tumor masses in the liver, leading to the death of the animals within 4-6 weeks after tumor cell inoculation (data Cancer Gene Therapy, Vol 8, No 8, 2001 not shown ). Histological examination of the highly vascularized tumors showed tumor infiltration as well as the formation of pseudocapsules. Areas of vital tumor tissue with pleomorphic HCC cells were found next to cystic and necrotic areas similar to findings in human HCC (Fig 1, C  and D ) . Cellular proliferation in intrahepatic tumor nodules was assessed by immunohistochemical detection of PCNA expression, which showed background staining in normal surrounding liver and high levels of PCNA expression in the tumorous tissue (Fig 1, E and F) .
Gene expression in liver tumors and surrounding normal liver tissue following intravenous administration of adenovirus vectors
To determine the expression of -galactosidase expression in the orthotopic HCC model following systemic intravenous adenovirus administration, 10 10 IU Ad2CMVgal was injected into the tail vein of nude mice bearing intrahepatic HCCs. Mice were sacrificed 2 days later. Frozen sections from tumor tissue and from different regions of the nontumorous livers were stained with X -gal or tissue homogenates were analyzed for -galactosidase expression by a chemiluminescence assay. High levels of -galactosidase expression were found in the liver, where up to 90% of hepatocytes was transduced by the adenoviral vector (Fig  2A ) . In contrast, only few single HCC cells expressinggalactosidase could be identified within intrahepatic tumors ( Fig 2, B and C ) . Quantification of reporter gene expression confirmed extremely low levels of gene expression in the tumorous tissue compared to the nontumorous liver tissue (Fig 2D) . 
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Gene expression in liver tumors and surrounding normal liver tissue following direct intratumoral injection of adenovirus vectors
Following direct administration of adenoviral vectors into intrahepatic HCCs, high levels of reporter gene expression could be detected in the tumor tissue. We found up to 30% of tumor cells transduced, but the distribution of -galactosidase -expressing cells was inhomogeneous and showed areas with high transduction levels next to areas of virtually no transduction of tumor cells ( Fig 3A ) . In the liver tissue directly adjacent to the injected tumors, few areas with groups of transduced hepatocytes were detected (Fig 3B ) . More importantly, in liver tissue distant to the injected tumors, single hepatocytes expressing -galactosidase scattered throughout the liver parenchyma could be identified (Fig 3, B and C ) . Quantification of gene expression in tumor tissue and liver tissue confirmed the enhanced levels of gene expression in the tumor tissue following direct tumor injection. However, significant levels of gene expression could also be demonstrated in nontumorous liver tissue ( Fig  3D ) .
DISCUSSION
For gene therapy to become a realistic option for the treatment of HCC, techniques of safe and efficient gene delivery into HCCs need to be established. Prior to future clinical trials, gene transfer in vivo has to be evaluated in appropriate animal models. Due to technical simplicity, most gene therapy studies are performed in subcutaneous tumors derived from murine or human tumor cell lines grown in syngeneic recipient mice or in athymic nude mice. 10, 12, 14 These tumors are easily accessible to experimental procedures and to serial measurements of tumor growth. These models are useful for the basic evaluation of the efficiency of novel gene therapy approaches in vivo, but do not reflect the realistic clinical situation of human HCC. To be able to analyze the efficiency of gene delivery and therapeutic efficiency as well as he potential side effects specifically for the clinical situation of HCC, intrahepatic HCC models are required. In the present study, we describe a model of orthotopic HCC in the livers of nude mice. The histological analysis of these tumors closely resembled the histological findings of human HCC. Furthermore, previous studies suggested a predominant blood supply by the hepatic artery, which also mimics the realistic clinical situation. 23 Although this model may be more artificial as compared to the costly and time -consuming HCC models in transgenic mice 24 or to carcinogen -induced HCCs in rats, 25, 26 our intrahepatic HCC model in nude mice exhibits several advantages. Following tumor cell injection, up to 90% of animals reproducibly develop intrahepatic tumors within 10 -14 days, which can be detected macroscopically during a second -look laparotomy long before animals show signs of malignant disease. The detection of tumors in a similar early stage in transgenic animals or in animals treated with carcinogens involves long -term observation of a large number of animals and close monitoring of tumor development by regular killing of animals.
We used our intrahepatic HCC model to analyze transduction of HCC cells in intrahepatic tumors and in the surrounding normal liver by recombinant adenoviral vectors because these vectors exhibit several potential advantages for gene therapy of hepatocyte -derived tumors such as HCC. Adenoviruses are highly hepatotrophic. 27, 28 Furthermore, these vectors are relatively easy to produce and high titers of recombinant adenovirus particles may be obtained. 29 Their intrinsic stability allows for efficient intravenous and direct intratumoral delivery. Adenoviruses do not integrate into the host genomic DNA, which reduces the risk of insertional mutagenesis. 30 Furthermore, the limited period of gene expression following adenoviral gene transfer represents a potential therapeutic advantage with respect to the safety of gene therapy approaches. 31 However, the immune response against adenoviral proteins limits repeated administration in vivo 32, 33 and intravenous delivery of high titers of adenoviral vectors may induce severe hepatic inflammation. 34, 35 We used the intrahepatic HCC model in nude mice to evaluate gene transfer by recombinant adenovirus vectors by two different routes of administration. Following intravenous injection of adenovirus vectors, we observed minimal transduction efficiency of HCC cells in intrahepatic tumors. This finding is supported by previous studies on adenoviral gene delivery in other intrahepatic HCC models. 24, 26 In contrast to the findings in intrahepatic tumors, we observed high levels of transduction in the surrounding normal hepatocytes. This indicates that adenovirus vectors efficiently reached the liver via the blood supply, suggesting that tumor-specific factors impair efficient transduction of intrahepatic HCCs. Normal liver sinusoids are fenestrated with an average fenestration size in hepatic sinusoids of 150 nm, 36 which allow adenoviruses to gain direct access to the cell surface of hepatocytes. In contrast, malignant neoplastic blood vessels in the liver are of a different basic biological type compared to normal hepatic sinusoids 37 and may lack endothelial fenestrations. Furthermore, increased interstitial pressure within a tumor nodule 38 may further reduce penetration by adenovirus vectors. In a recent report, Bilbao et al 25 described a blood -tumor barrier for adenoviral vectors between normal liver tissue and intrahepatic HCCs in a diethylnitrosamine -induced HCC model in rats and found that thickness and impermeability of this barrier were increased in larger tumor nodules. Transduction of tumor cells in tumor nodules could be enhanced either by selective administration of adenovirus vectors into the hepatic artery 39 or by intraarterial infusion of vasoactive compounds. 25 However, despite these attempts, the striking difference between highly efficient transduction of normal hepatocytes and the low transduction rate in intrahepatic tumors is of great concern. To prevent damage of normal hepatocytes caused by the expression of therapeutic genes, transgene expression may be restricted to tumor cells by tumorspecific promoters such as the -fetoprotein (AFP ) promoter. Previous studies have demonstrated therapeutically efficient transgene expression restricted to AFPpositive HCC cells. 10 -12 Human HCCs frequently express the oncofetal protein AFP at high levels, 40, 41 but low -level AFP expression is also reactivated in regenerating liver tissue and in patients with liver cirrhosis. Due to the enhanced uptake of adenovirus vectors into normal hepatocytes, derepression of the AFP promoter even in a low percentage of hepatocytes could lead to substantial levels of expression of therapeutic genes in normal hepatocytes, which could result in a serious damage of liver tissue in HCC patients. In addition, viral infection of a high percentage of hepatocytes might induce severe inflammation by immune responses directed against adenoviral proteins. As reported previously, severe toxicity was observed following adenoviral gene delivery in transgenic mice bearing intrahepatic HCCs. 24 Before intravenous or intraarterial delivery of adenovirus vectors might be considered as an option for gene therapy of HCC, safety issues have to be analyzed in detail in appropriate animal models.
To prevent excessive transduction of normal hepatocytes, we also performed direct injection of adenovirus vectors into intrahepatic HCCs and analyzed gene transfer into tumor cells and normal hepatocytes. By this route of administration, we observed a high transduction efficiency in the tumor tissue, although there was an inhomogeneous distribution of areas highly transduced and areas with virtually no transduced HCC cells. However, up to 30% of the tumor cells could be transduced by this technique, which would be sufficient for effective gene therapy using suicide genes exhibiting a strong bystander effect 14 or using immunomodulatory genes. 15, 16, 18, 19 As the technique of ultrasoundguided injection of ethanol or acetic acid into intrahepatic tumors 42 is routinely used in clinical practice, direct injection into HCCs might become a feasible route of vector administration for future gene therapeutic approaches. However, despite the high transduction efficiency in the tumor tissue, we observed transduced hepatocytes scattered throughout the liver parenchyma, which were most likely infected by recirculating adenovirus vectors having being drained into the circulation from the injected tumors. This observation might have important clinical impact, as HCCs are highly vascularized and therefore direct injection of HCCs with adenoviral vectors could result in a substantial number of transduced normal hepatocytes. This potential risk could be overcome by introduction of an additional level of safety such as tumor-specific targeting of adenoviral vectors. We have recently demonstrated specific targeting of an adenoviral vector to human HCC cells using a bifunctional Fab-antibody conjugate. 43 Therefore, the combination of direct injection of adenovirus vectors specifically targeted to human HCC cells could become an option for safe and efficient gene therapy of human HCC.
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